[Business Wire] – Gilead Sciences, Inc. today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
Read more on this.
Gilead Sciences Inc. (GILD), currently valued at $124.26B, began trading this morning at $79.31.
Looking at today’s trading action, the company’s one day range from $78.80 to $81.13 and has traded between $40.16 and $84.40 over the past year.
GILD shares are currently priced at 21.52x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -10.31x earnings multiple for the same period.
According to a consensus of 23 analysts, the earnings estimate of $0.78 per share would be $0.30 better than the year-ago quarter and a $0.17 sequential increase. The full-year EPS estimate is $3.66 which would be a $1.62 better than last year’s full-year earnings.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $3.61 Billion. If realized, that would be a 42.69% increase over the year-ago quarter.
More recently, Robert W. Baird upgraded GILD from Neutral to Outperform (Feb 4, 2014). Previously, Robert W. Baird downgraded GILD from Outperform to Neutral.
When considering if perhaps the stock is under or overvalued, the average price target is $99.48, which is 25.43% above where the stock opened this morning.
Gilead Sciences Inc (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe and Asia.
Tag Helper ~ Stock Code: GILD | Common Company name: Gilead | Full Company name: Gilead Sciences Inc (NASDAQ:GILD) .